{"id":"at-527-and-probenecid","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"5%","effect":"Vomiting"},{"rate":"8%","effect":"Diarrhea"},{"rate":"12%","effect":"Headache"},{"rate":"15%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL897","moleculeType":"Small molecule","molecularWeight":"285.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AT-527 works by inhibiting the RNA-dependent RNA polymerase of SARS-CoV-2, which is essential for the replication of the virus. Probenecid, on the other hand, increases the renal excretion of uric acid, making it a treatment for gout.","oneSentence":"AT-527 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, and Probenecid is a uricosuric agent that increases the renal excretion of uric acid.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:55:41.409Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19"}]},"trialDetails":[{"nctId":"NCT05618314","phase":"PHASE1","title":"Study of AT-527 in Subjects With Normal and Impaired Renal Function","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2022-10-17","conditions":"Healthy Volunteer, Renal Impairment","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bemnifosbuvir"],"phase":"phase_1","status":"active","brandName":"AT-527 and Probenecid","genericName":"AT-527 and Probenecid","companyName":"Atea Pharmaceuticals, Inc.","companyId":"atea-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AT-527 is a small molecule inhibitor of the solute carrier family 22 member 6, and it has been studied in combination with probenecid in a Phase 1 clinical trial to evaluate its safety and pharmacokinetics in adult subjects with normal and impaired renal function. Probenecid, also known as probalan, is a known inhibitor of the same molecular target as AT-527.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}